Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.36 |
| ▸ | CDK2 | P24941 | 3/20 | 0.36 |
| ▸ | CDK9 | P50750 | 3/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5913877 | 1.00 | MAPK14 (0.38) | MAPK14CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL5314959 | 0.92 | MAPK14 (0.40) | MAPK14KDR | |
| SCHEMBL5314967 | 0.92 | MAPK14 (0.40) | MAPK14KDR | |
| SCHEMBL5914082 | 0.90 | MAPK14 (0.39) | MAPK14MAPK1KDR | |
| SCHEMBL5914162 | 0.89 | HPGDS (0.40) | MAPK14MAPK1KDM5AKDM4CKDM5B | |
| SCHEMBL5914169 | 0.89 | HPGDS (0.40) | MAPK14MAPK1KDM5AKDM4CKDM5B | |
| SCHEMBL5914118 | 0.86 | MAPK14 (0.42) | MAPK14MAPK1KDR | |
| SCHEMBL5914204 | 0.84 | MAPK14 (0.38) | MAPK14KDR | |
| SCHEMBL5914210 | 0.84 | MAPK14 (0.38) | MAPK14KDR | |
| SCHEMBL5264280 | 0.82 | MAPK14 (0.40) | MAPK14MAPK1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | MAPT, MYLK2, IAPP | MAPK14 2620/4885CCNT1 369/4885CCNA2 2516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.